purchase agreement and/or relevant agreements and complete the transfer of BS Myco Biotech shares on June 12, 2019. This Acquisition is considered as the assets acquisition transaction of listed company and
debt to equity ratio not exceeding 5:1, which will appear in the annual financial statements for 2025 and 2026; (5) Approving other actions related to the bond series, with
2018, the Company, Pace Project One Co., Ltd. (“PP1”), Pace Project Three Co., Ltd. (“PP3”), and a director entered into buyout agreement on disposal of assets in PP1 and PP3 in total of not exceeding to
precedent specified in the share purchase agreement are fulfilled. Upon consummation of the Share Acquisition Transaction, the Company will be the shareholder of Hero Experience holding shares equivalent to
(25.42%) (48.98%) (25.08%) Other Expenses Loss on cancel of joint venture agreement - (15.92 ) 15.92 (100.00%) 0.00% (7.28%) Impairment loss of land held for development - (5.83 ) 5.83 100.00% 0.00% (2.67
for sales staff, traveling and vehicle expense for sales staff, cost of advertisement media for product promotion, compensation paid to Zuellig Pharma Ltd. under the Distribution Agreement and
expense for sales staff, cost of advertisement media for product promotion, compensation paid to Zuellig Pharma Ltd. under the Distribution Agreement and compensation for distribution of the Company’s
expenses 2.86 5.13 2.54 4.70 (0.32) (11.19) Profit for the period 16.69 29.94 13.60 25.17 (3.09) (18.51) Profit for Equity holders of the Company 16.70 29.96 13.64 25.25 (3.06) (18.32) Profit for Non
. Total liabilities increased as a result of the share purchase agreement of KURON Co., Ltd. Since 3 March 2020 and deferred tax liability. Shareholders’ Equity As of 30 September 2020, shareholders’ equity